- 2024, Volume 82 - Number 2
- Published: May 20, 2024
Dupilumab in pediatric atopic dermatitis: real-world evidence from two national centers
Gilberto P. da Rosa 1, Patrícia Amoedo 2, Pedro Matos 2, Ana Pedrosa 3, Ana Nogueira 2, Catarina Vilarinho 4, Fernando Mota 4, Maria J. Cruz 5, Filomena Azevedo 6 
, Alberto Mota 7
1 Department of Dermatology and Venereology, São João Local Health Unit; Department of Medicine, Faculty of Medicine, University of Porto; Porto, Portugal; 2 Department of Dermatology and Venereology, Centro Hospitalar Universitário de São João, Porto, Portugal; 3 Department of Dermatology and Venereology, Centro Hospitalar Universitário de São João, Porto; Department of Medicine, Faculty of Medicine, University of Porto, Porto; Portugal; 4 Department of Dermatology and Venereology, Hospital da Senhora da Oliveira, Guimarães, Portugal; 5 Department of General Surgery, Unidade Local de Saúde de São João, Porto, Portugal; 6 Department of Dermatology and Venereology, São João Local Health Unit, Porto, Portugal; 7 Department of Dermatology and Venereology, São João Local Health Unit; Department of Medicine, Faculty of Medicine, University of Porto; CINTESIS@RISE, Center for Health Technology and Services Research, Faculty of Medicine, University of Porto. Porto, Portugal
Gilberto P. da Rosa, Patrícia Amoedo, Pedro Matos, Ana Pedrosa, Ana Nogueira, Catarina Vilarinho, Fernando Mota, Maria J. Cruz, Filomena Azevedo, Alberto Mota
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondence: Alberto Mota, Email not available
Abstract
Objective: The use of dupilumab in children with atopic dermatitis (AD) demonstrated clinical efficacy in clinical trials. Nevertheless, real-world evidence is still limited. We aim to provide data on this matter regarding a Portuguese pediatric population. Methods: Retrospective analysis of patients with AD below the age of 18 treated with dupilumab in two Portuguese hospitals. Data regarding previous therapies, activity scores, and adverse reactions were collected. Results: Thirty patients were included in the analysis (19 male patients, 63%), with a median age of 14 years (2-17 years). The median follow-up after starting treatment was 80 weeks. The median baseline Eczema Area and Severity Index (EASI) score was 32.3. Sixty percent of patients achieved EASI-90 and 77% EASI-75 at week 16 (n = 30); 79% EASI-90 and 92% EASI-75 at week 52 (n = 24); 64% EASI-90 and 82% EASI-75 at week 104 (n = 11); and 75% EASI-90 and 100% EASI-75 at week 132 (n = 4). Regarding adverse reactions, four patients (12%) presented facial erythema and two patients had eosinophilia above 2000/μL and conjunctivitis. In five patients (17%), there was a need for a dose increase, with treatment failure occurring in two patients (7%). Conclusion: Our data corroborated the evidence from clinical trials, highlighting the maintained efficacy and adequate safety profile of dupilumab in this age group.
